Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection

NCT04308278 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

88

Enrollment

INDUSTRY

Sponsor class

Conditions

EBV Infection

Interventions

DRUG: 2LEBV® / 2LXFS®
DRUG: Placebo

Sponsor

Labo'Life